FOR IMMEDIATE RELEASE
Continuing Medical Education Company—PER®—Hosts Conference Conducted by Cancer Experts
Plainsboro, N.J. – July 17, 2013 – Physicians’ Education Resource® (PER®), the go-to source for excellence in continuing medical education, will honor Dr. Tony Mok of Chinese University of Hong Kong as the recipient of the 2013 Addario Lectureship Award at the 14th International Lung Cancer Congress®. The Congress, hosted by PER®, will be held on July 25 – 27 at the Hyatt Regency in Huntington Beach, California.
Each year the Bonnie J. Addario Lung Cancer Foundation (BJALCF) recognizes luminaries in the quest to eradicate lung cancer with the Addario Lectureship Award. Dr. Mok will deliver his keynote lecture on the global impact of lung cancer. The Bonnie J. Addario Lung Cancer Foundation has supported the International Lung Cancer Congress® for the past six years and joins the International Association for the Study of Lung Cancer (IASLC) as co-sponsors of the Congress.
Dr. Mok, who serves as IASLC’s president-elect, is renowned for his research into genomic abnormalities between different populations of patients with non-small cell lung cancer (NSCLC) that could lead to more individualized treatment. He has helped author more than 100 journal articles, reviewed numerous targeted therapies for NSCLC, and has been very active in both clinical and laboratory research. He also chairs the Hong Kong Cancer Therapy Society and is an executive committee member of the Chinese Society of Clinical Oncology.
“We are thrilled to honor Dr. Mok at the International Lung Cancer Congress and share his insights about lung cancer’s impact around the world,” said David DePinho, PER®’s general manager. “We also applaud the ongoing commitment and efforts of the Addario Foundation and IASLC as we work jointly to advance the care of lung cancer.”
The three-day International Lung Cancer Congress provides physicians with practical information regarding the clinical implications of lung cancer screening, the latest clinical data impacting the treatment of lung cancer, and novel agents and strategies that are changing the future of lung cancer therapy. It is co-chaired by David Gandara, MD, Director of the Thoracic Oncology Program and Associate Director of Clinical Research at the University of California, Davis Cancer Center; and Roy S. Herbst, MD, PhD, Chief of Medical Oncology at Yale Comprehensive Cancer Center.
“We are proud of our continued partnership with the International Lung Cancer Congress because they provide a place for people to listen and think differently about how to treat lung cancer. And more importantly, they value the patient in that process,” said Bonnie J. Addario, lung cancer survivor and founder of the Bonnie J. Addario Lung Cancer Institute. “We are also proud to be honoring Dr. Tony Mok because he is driven and passionate about working for the patient, and he is doing it on a worldwide scale.”
This year, one of the many topics of discussion will be guidelines issued by IASLC, the College of American Pathologists, and the Association for Molecular Pathology on molecular testing for EGFR and ALK gene mutations, including standards for the tests and optimal use of therapies directed against those abnormalities.
“Dr. Mok is an internationally recognized expert in lung cancer individualized therapy. He was the principal investigator on the groundbreaking trial demonstrating that a single, oral tyrosine kinase inhibitor, gefitinib, provided superior outcomes compared to multi-agent intravenous cytotoxic chemotherapy,” said Dr. Paul Bunn, Executive Director of IASLC. “This study revolutionized the way we study and treat advanced lung cancers.
PER® is accredited by the Accreditation Council for Continuing Medical Education to provide learning opportunities for physicians. PER® plans, develops, implements and evaluates educational opportunities, incorporating instructional design with principles of adult learning, including multi-day congresses, one-day update meetings, traditional dinner meetings, online case discussions, and faculty dialogues with the ultimate goal of improving patient outcomes.
To learn more, visit www.gotoper.com.
About Physicians’ Education Resource®, LLC
Accredited by the Accreditation Council for Continuing Medical Education (ACCME), Physicians’ Education Resource® (PER®) is the certified medical education resource of choice for live and online activities focusing on oncology and hematology. Based on identified needs and practice gaps, PER® provides high-quality, evidence- based activities featuring leading national and international faculty with a focus on practice changing advances and standards of care in treatment and disease management. PER® serves the oncology health care community, including physicians, fellows, physician assistants, advanced practice nurses, nurses, pharmacists, and researchers. Learn more at www.gotoper.com.
About the Bonnie J. Addario Lung Cancer Foundation (BJALCF)
BJALCF is one of the largest philanthropies (patient-founded, patient-focused, patient-driven) devoted exclusively to eradicating Lung Cancer through research, early detection, education, and treatment. The Foundation works with a diverse group of physicians, organizations, industry partners, individuals, survivors, and their families to identify solutions and make timely and meaningful change. BJALCF was established on March 6, 2006 as a 501©(3) non-profit organization and has raised over nine million dollars for Lung Cancer research.
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 3,500 lung cancer specialists in 80 countries. To learn more about IASLC please visit www.iaslc.org.
For Physicians’ Education Resource®, LLC